Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
United Airlines Eyes Merger with American Airlines in Potential Industry-Shaping Deal 
Anthropic Discusses Frontier AI Model Mythos With Trump Administration Despite Pentagon Ban 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
PARSIPPANY, N.J., June 01, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Jefferies 2017 Global Healthcare Conference at 1:30 PM ET on Tuesday, June 6, 2017 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
